Zoetis Inc. (NYSE:ZTS) Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,351 shares of the company’s stock after selling 2,622 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Zoetis were worth $662,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Blue Bell Private Wealth Management LLC increased its holdings in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after purchasing an additional 89 shares during the period. Independence Bank of Kentucky increased its holdings in shares of Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Moisand Fitzgerald Tamayo LLC increased its holdings in shares of Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock valued at $33,000 after acquiring an additional 96 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of Zoetis in the 3rd quarter valued at about $35,000. Finally, First Financial Corp IN increased its holdings in shares of Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after acquiring an additional 79 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS traded up $1.32 during mid-day trading on Wednesday, hitting $150.88. The company’s stock had a trading volume of 3,574,932 shares, compared to its average volume of 3,068,309. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a 50-day simple moving average of $173.78 and a 200 day simple moving average of $179.78. The firm has a market capitalization of $69.01 billion, a P/E ratio of 29.75, a P/E/G ratio of 2.22 and a beta of 0.85. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.15 earnings per share. Analysts predict that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a yield of 1.15%. Zoetis’s dividend payout ratio is presently 34.12%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. The Goldman Sachs Group raised their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Barclays dropped their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday. Stifel Nicolaus dropped their price target on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $218.00.

Insider Buying and Selling

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders sold 2,209 shares of company stock valued at $371,293. 0.15% of the stock is owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.